RECCE PHARMACEUTICALS LTD — Board/Management Information 2018

Apr 23, 2018

ASX Announcement

Pharmaceutical Expert Joins Board of Directors

SYDNEY, Australia, 24 April 2018: Recce Pharmaceuticals Ltd (ASX: RCE) ( Recce or the Company ), developing a new class of synthetic antibiotics, today announced the appointment of Dr John Prendergast to its Board as an independent Non-Executive Director.

Dr Prendergast brings significant international experience in commercialising pharmaceuticals for global markets, most notably in the USA.

He is currently Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN), a US biotechnology company capitalised at over US$260m, developing therapeutics for diseases with significant unmet medical need; Lead Director of Heat Biologics, Inc. (NASDAQ: HTBX) and Cofounder/Executive Chairman of Nejo, Inc.

Dr Prendergast said, "I am pleased to join Recce's Board at a pivotal time in the Company’s development, as its new class of antibiotics continues to show significant promise in tackling the global health problem of superbugs. I look forward to supporting the Company's development program."

Executive Chairman Dr Graham Melrose said, “We welcome Dr Prendergast to the Board at a key point in our regulatory and commercial development. His experience in the US market will be invaluable as we progress our lead compound towards clinical trials in the USA.”

Additional professional background for Dr Prendergast

Dr Prendergast has further held previous US biotechnology Board positions, most notably Lead Director of MediciNova, Inc. valued at over US$470m (Nasdaq:MNOV) and Osaka Securities Exchange (#4875) and Co-founder/Lead Director of Avigen, Inc. which was acquired by MediciNova in 2009 for US$37m. Prior to a career in commercialising pharmaceutical technologies, Dr Prendergast was Managing Director of Paramount Capital Investments and The Castle Group. Dr

==> picture [595 x 124] intentionally omitted <==

Prendergast has also served as a member of the Advisory Board for the Institute for the Biotechnology of Infectious Diseases (IBID) at the University of Technology Sydney, now called the ithree institute. An Australian citizen based in the USA, Dr Prendergast received his M.Sc. and Ph.D. degrees from the University of New South Wales, Sydney and a C.S.S. in Administration and Management from Harvard University. He has held Post-Doctoral Fellowships in the Department of Biochemistry and Molecular Biology, at Harvard University, and the Institute for Blood Diseases at L'Hospital St. Louis in Paris, France.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-man clinical trials.

For further information please visit www.recce.com.au or contact:

Investor Relations James Graham Executive Director Recce Pharmaceuticals Ltd Tel: +61 (02) 8075 4585

Media (Australia) Andrew Geddes CityPR Tel: +61 (02) 9267 4511

Media (International) Sue Charles/Gemma Harris Instinctif Partners Tel: +44 (0)20 7866 7860 E: recce@instinctif.com

==> picture [595 x 74] intentionally omitted <==